US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April